Please assess the completion status of the following clinical trial:

Trial Title: Comparing Double Dose of Vaginal Progesterone to no Treatment for Prevention of Preterm Birth in Twins and Short Cervix

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Twin gestation~* Certain dating (documented first trimester ultrasound, or a reliable menstrual date confirmed by an ultrasound performed before 20 weeks of gestation)~* Age \> 18 years~* Gestational age 16-26~* Cervical length\<25 mm~* Intact membranes~* Informed consent~Exclusion Criteria:~* Major malformation or chromosomal abnormality to at least one fetus~* Higher order pregnancy~* Mocochorional-monoamniotic twin~* Death of one fetus~* Cervical dilatation \>3 cm~* Chronic medical conditions that would interfere with study participation or evaluation of the treatment (e.g. seizures, psychiatric disorders, uncontrolled chronic hypertension, congestive heart failure, chronic renal failure, uncontrolled diabetes mellitus with end-organ dysfunction, active thrombophlebitis or a thromboembolic disorder, history of hormone-associated thrombophlebitis or thromboembolic disorders, active liver dysfunction or disease, known or suspected malignancy of the breast or genital organs)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Treatment with 400 mg Micronized progesterone (Utrogestan) daily up to 6 weeks of geastation
- No treatment (Type: NO_INTERVENTION): No treatment. Regular follow up

Based on this trial design, predict the completion outcome and termination type (if applicable).